Header
Call for support 1-833-295-8396
Woman throwing an object

Adalimumab-adbm is:

  • A biosimilar that is interchangeable to Humira®*

  • The exact same medicine as CYLTEZO

  • As effective and safe as Humira

  • Injected under the skin, using either an injection pen or a prefilled syringe

  • Citrate-free

  • Made in the US

Patient opening up Adalimumab-adbm
  • *
    The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. CYLTEZO (100 mg/mL) was approved as an interchangeable biosimilar to Humira on May 20, 2025. For more information on interchangeability for CYLTEZO, refer to the FDA’s resource on biosimilars and interchangeability, the Purple Book: https://purplebooksearch.fda.gov/.

Adalimumab-adbm is a citrate-free, injectable prescription medicine called a tumor necrosis factor (TNF) blocker that is used for the following conditions:

  • Rheumatoid arthritis (moderate to severe)

  • Chronic plaque psoriasis (moderate to severe)

  • Crohn’s disease (moderate to severe)

  • Psoriatic arthritis

  • Ulcerative colitis (moderate to severe)

  • Ankylosing spondylitis

  • Hidradenitis suppurativa (moderate to severe)

  • Polyarticular juvenile idiopathic arthritis (moderate to severe)

  • Non-infectious intermediate, posterior, and panuveitis

Click here for full indications for Adalimumab-adbm and CYLTEZO.

Common side effects icon

Adalimumab-adbm side effects are similar to Humira

The most common side effects of Adalimumab-adbm included injection site reaction (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), and headaches.

These are not all the possible side effects with Adalimumab-adbm. Tell your doctor if you have any side effect that bothers you or that does not go away. Tell your doctor if you think you have an infection or have symptoms of an infection, such as fever, sweats, or chills; muscle aches; cough; shortness of breath; blood in phlegm; warm, red or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal; feel very tired; and/or weight loss. Adalimumab-adbm can make you more likely to get infections or make any infection that you may have worse.

Click here to read Important Safety Information.

savings card

Eligible patients may pay as little as $0 for Adalimumab-adbm

The CareConnect4MeTM Adalimumab-adbm Copay Program may help eligible patients who have commercial insurance, including through a health insurance exchange, federal employee plan, or state employee plan, pay as little as $0 per fill of Adalimumab-adbm.

Terms and Conditions apply.

Learn how to save

Frequently asked questions

About Adalimumab-adbm and CYLTEZO

Expand all

Adalimumab-adbm, a biosimilar to Humira, may treat or reduce the signs and symptoms of certain autoimmune conditions. See Important Safety Information about Adalimumab-adbm.

Adalimumab-adbm is an interchangeable* biosimilar to Humira. Adalimumab-adbm and CYLTEZO are the exact same medicine. Both Adalimumab-adbm and Humira are adalimumab products, and Adalimumab-adbm has been tested to make sure it is as effective and safe as Humira.

* The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. CYLTEZO (100 mg/mL) was approved as an interchangeable biosimilar to Humira on May 20, 2025. For more information on interchangeability for CYLTEZO, refer to the FDA’s resource on biosimilars and interchangeability, the Purple Book: https://purplebooksearch.fda.gov/.

Biologics are a type of medication made with a living source, such as a microorganism, plant cell, or animal cell.

A biosimilar, such as Adalimumab-adbm, is a type of biologic created based on a reference product. In this case, Humira is the reference product. A biosimilar is highly similar to and has no difference in safety and effectiveness from the existing FDA-approved reference product.

An interchangeable biosimilar generally requires an additional study, such as a switch study, before being approved by the FDA. The study must show that patients experienced no difference in effectiveness or increase in safety risk when switching back and forth between the original biologic, or reference, product and biosimilar, compared with those who remained on the original biologic product.

Yes, Adalimumab-adbm and CYLTEZO are the exact same medicine with the same effectiveness and safety.

Adalimumab-adbm and CYLTEZO are the exact same medicine with the same effectiveness and safety. Whether you receive Adalimumab-adbm or CYLTEZO depends on which product is covered by your insurance plan. A specialty pharmacy may have worked with your healthcare provider and insurance company for you to receive Adalimumab-adbm.

Effectiveness, safety, and side effects

Expand all

Yes. A range of clinical studies with adalimumab showed the medication to be effective and safe in the treatment of rheumatoid arthritis, plaque psoriasis, Crohn’s disease, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, juvenile idiopathic arthritis, and uveitis.

The FDA designated Adalimumab-adbm as an interchangeable* biosimilar to Humira. Adalimumab-adbm and CYLTEZO are the exact same medicine, and the FDA designated Adalimumab-adbm as an interchangeable* biosimilar to Humira. This designation was based on an additional study in which patients were switched back and forth from Humira to CYLTEZO, with no change in effectiveness or safety in any given patient. The FDA only gives the interchangeable designation based on additional information. This is generally from one or more studies that confirm the biosimilar's effectiveness and safety are the same as the original branded product in any given patient.

* The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. CYLTEZO (100 mg/mL) was approved as an interchangeable biosimilar to Humira on May 20, 2025. For more information on interchangeability for CYLTEZO, refer to the FDA’s resource on biosimilars and interchangeability, the Purple Book: https://purplebooksearch.fda.gov/.

Adalimumab-adbm is a medicine that affects your immune system. It can lower the ability of your immune system to fight infections. Serious infections have happened in people taking adalimumab products. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections.

Your doctor should test you for TB before starting Adalimumab-adbm. Your doctor should check you closely for signs and symptoms of TB during treatment with Adalimumab-adbm.

You should not start taking Adalimumab-adbm if you have any kind of infection unless your doctor says it is okay.

The FDA approved Adalimumab-adbm as a biosimilar and additionally designated Adalimumab-adbm (the exact same medicine as CYLTEZO) as an interchangeable* biosimilar to Humira. This designation was based in part on data from an additional study, in which patients were switched back and forth from Humira to CYLTEZO, with no meaningful difference in effectiveness or safety compared with patients who remained on Humira.

* The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. CYLTEZO (100 mg/mL) was approved as an interchangeable biosimilar to Humira on May 20, 2025. For more information on interchangeability for CYLTEZO, refer to the FDA’s resource on biosimilars and interchangeability, the Purple Book: https://purplebooksearch.fda.gov/.

The most common side effects of Adalimumab-adbm include injection site reactions: redness, rash, swelling, itching, or bruising. These are not all the possible side effects with Adalimumab-adbm. Tell your doctor if you have any side effect that bothers you or that does not go away. Additional side effects include upper respiratory infections (including sinus infections), headaches, and rash.

Tell your doctor if you have any side effect that bothers you or that does not go away. Tell your doctor if you think you have an infection or have symptoms of an infection, such as fever, sweats, or chills; muscle aches; cough; shortness of breath; blood in phlegm; warm, red or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal; feel very tired; and/or weight loss. Adalimumab-adbm can make you more likely to get infections or make any infection that you may have worse.

For full details, please see the Medication Guide.

You can expect the same results that you experienced with Humira.

Your doctor can provide guidance on the efficacy of Adalimumab-adbm for your condition. If you have any questions regarding the use of Adalimumab-adbm or if you experience any side effects, please contact your doctor right away. If you are starting treatment with adalimumab, please follow your doctor's prescription. You can refer to the full Prescribing Information for more information about Adalimumab-adbm. If you do not notice any improvement or experience worsening of symptoms after several weeks, consult with your doctor to determine if Adalimumab-adbm is the appropriate medication for you.

For patients switched from Humira to Adalimumab-adbm, you can expect the same clinical results as Humira immediately. Because you already had the required starting dose with Humira, you will start Adalimumab-adbm by continuing to take maintenance doses with Adalimumab-adbm.

Although some patients may experience positive results, others may not. Therefore, it is essential that you discuss with your doctor the efficacy of Adalimumab-adbm for your condition. If you have questions regarding the use of Adalimumab-adbm, please don't hesitate to speak with your doctor.

Before starting Adalimumab-adbm, you should tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Show your doctor and pharmacist a list of medicines you are currently taking when you are getting a new medicine.

Especially tell your doctor if you use ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab), because you should not use Adalimumab-adbm while you are also using one of these medicines. Your doctor may not want to give you Adalimumab-adbm if you have received RITUXAN® (rituximab) recently, IMURAN® (azathioprine), or PURINETHOL® (6-mercaptopurine, 6-MP).

Before starting Adalimumab-adbm, tell your doctor if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed. In such cases, Adalimumab-adbm may not be right for you. You and your doctor should decide if you should take Adalimumab-adbm while you are pregnant or breastfeeding.

If you have a baby and you were using Adalimumab-adbm during your pregnancy, tell your pediatrician before your baby receives any vaccines.

Talk to your doctor about which vaccines are right for you. You may receive vaccines, except for live vaccines, while using Adalimumab-adbm. It is recommended that pediatric patients, if possible, be up to date with all immunizations that follow current immunization guidelines before starting Adalimumab-adbm. Please speak with your pediatrician.

Taking Adalimumab-adbm

Expand all

Adalimumab-adbm is injected under the skin using either an Adalimumab-adbm pen or a prefilled syringe. Both were designed to be used at home so that you can inject on a set schedule, using the right dose prescribed by your doctor. Speak to your doctor before starting injections on your own to ensure that you have the proper injection training.

You can find information about how to inject CYLTEZO here.

The appropriate dosage of Adalimumab-adbm is prescribed by your doctor, based on your condition. Please follow the dosing instructions provided by your doctor.

Do not miss any doses of Adalimumab-adbm unless your doctor says it is okay. If you forget to take Adalimumab-adbm, inject a dose as soon as you remember. Then, take your next dose at your scheduled time. This will put you back on schedule. In case you are not sure when to inject Adalimumab-adbm, call your doctor or pharmacist.

If you take more Adalimumab-adbm than you were told to take, call your doctor.

Your Adalimumab-adbm prescription and shipment frequency will be determined by your doctor and your insurance coverage.

Contact your specialty pharmacy with questions regarding refills.

If one or more of your Adalimumab-adbm pens or prefilled syringes meets at least one of the following criteria, do not use it and contact the specialty pharmacy to request a replacement.

  • It is cracked, broken, or leaking

  • It has been frozen

  • It has been at room temperature for longer than 14 days

  • It has been exposed to direct light

  • The medicine has flakes or particles in it

  • The medicine is milky or discolored

  • Its expiration date has passed

You may use the Adalimumab-adbm products you have as long as they have not expired. Check the date on the packaging. If the expiration date has passed, discard the entire Adalimumab-adbm pen or prefilled syringe in your sharps disposal container, and use an Adalimumab-adbm pen or prefilled syringe that has not yet expired.

Storing Adalimumab-adbm

Expand all

Adalimumab-adbm must be refrigerated between 36° F and 46° F. Do not freeze Adalimumab-adbm. Do not use Adalimumab-adbm if frozen, even if it has been thawed. Do not store Adalimumab-adbm in extreme heat or cold. Adalimumab-adbm must be stored in its original carton until the time of injection to protect it from light.

If stored as directed, Adalimumab-adbm can be used up to the expiration date printed on the carton. Do not use Adalimumab-adbm after its expiration date.

No, you should not put Adalimumab-adbm back in the refrigerator after you have let it warm up to room temperature. However, Adalimumab-adbm may be stored at room temperature up to a maximum of 77° F for a period of up to 14 days, protected from light. If it is not used within that 14-day period, Adalimumab-adbm should be discarded.

Yes. When you are traveling, Adalimumab-adbm may be stored at room temperature up to a maximum of 77° F for a period of up to 14 days, protected from light. If it is not used within that 14-day period, Adalimumab-adbm should be discarded.

Adalimumab-adbm pens and prefilled syringes must be disposed of immediately after use using a sharps disposal container. Sharps disposal containers should be kept safely beyond the reach of children.

Savings and support

Expand all

Eligible, commercially insured patients may pay as little as $0 per dispense of Adalimumab-adbm. Once enrolled, patients will receive all details for the CARECONNECT4ME Adalimumab-adbm Copay Program to the email address they provide during enrollment. Please see terms and conditions.

Please call CARECONNECT4ME at 1-833-295-8396 Monday-Friday from 8:00 AM to 8:00 PM ET if you have any questions about the CARECONNECT4ME 
Adalimumab-adbm Copay Program.

Upon enrolling, you will receive all details for the CARECONNECT4ME Adalimumab-adbm Copay Program to the email address provided during enrollment. This copay information will include the BIN, PCN, member ID, and group ID numbers, which you can provide directly to the specialty pharmacy when they call you to set up delivery of Adalimumab-adbm. The specialty pharmacy will apply your copay information to help lower your out-of-pocket costs and will note the card number in your record for future refills. If you have questions about the CARECONNECT4ME Adalimumab-adbm Copay Program, call CARECONNECT4ME at 1-833-295-8396 Monday-Friday from 8:00 AM to 8:00 PM ET.

If you are not eligible for the CARECONNECT4ME Adalimumab-adbm Copay Program, you can speak with your specialty pharmacy to discuss other potential financial assistance options or speak with your healthcare provider.

Different insurance plans cover Adalimumab-adbm. You may have been prescribed Adalimumab-adbm because your insurance plan covers it. With the CARECONNECT4ME Adalimumab-adbm Copay Program, eligible patients may pay as little as $0 per fill for Adalimumab-adbm. Terms and conditions apply and may change without notice.

How much you pay for Adalimumab-adbm will depend on your insurance coverage. With the CARECONNECT4ME Adalimumab-adbm Copay Program, eligible patients with commercial insurance, including health insurance exchanges, federal employee plans, or state employee plans, pay as little as $0 per fill for Adalimumab-adbm. Terms and conditions apply and may change without notice. Patients on any state or federally funded insurance programs, including Medicare or Medicaid, Medigap, VA, DOD, or Tricare, are not eligible.

To see if you are eligible or have questions about your affordability options, please call CARECONNECT4ME at 1-833-295-8396 Monday-Friday from 8:00 AM to 
8:00 PM ET.

The price of Adalimumab-adbm or Humira is based on an individual’s insurance plan or eligibility for the savings program offered by each brand. Learn more about savings with the CARECONNECT4ME Adalimumab-adbm Copay Program.

If you have Medicare, Medicaid, or another government-funded plan, our CARECONNECT4ME team can answer questions and help you understand what costs may or may not be covered. To learn more, call our CARECONNECT4ME team at 1-833-295-8396 Monday-Friday from 8:00 AM to 8:00 PM ET.

You must be enrolled in the CARECONNECT4ME Adalimumab-adbm Copay Program to receive reimbursement. However, if your insurance plan did not accept your Adalimumab-adbm copay assistance information, or if you paid your copay because you were not enrolled in CARECONNECT4ME, we may be able to reimburse you for certain out-of-pocket costs. Download the CARECONNECT4ME Adalimumab-adbm Copay Program Prescription Claim Form or contact CARECONNECT4ME at 1-833-295-8396 Monday-Friday from 8:00 AM to 8:00 PM ET to learn more. Terms and conditions apply and may change without notice.

If you experience any problems applying your copay information or you cannot locate your CARECONNECT4ME Adalimumab-adbm Copay Program Welcome Email, please contact CARECONNECT4ME at 1-833-295-8396 Monday-Friday from 8:00 AM to 8:00 PM ET.

What is Adalimumab-adbm?

Adalimumab-adbm is a medicine called a tumor necrosis factor (TNF) blocker. Adalimumab-adbm is used:

  • To reduce the signs and symptoms of:
    • moderate to severe rheumatoid arthritis (RA) in adults. Adalimumab-adbm can be used alone, with methotrexate, or with certain other medicines.
    • moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years and older. Adalimumab-adbm can be used alone or with methotrexate.
    • psoriatic arthritis (PsA) in adults. Adalimumab-adbm can be used alone or with certain other medicines.
    • ankylosing spondylitis (AS) in adults.
    • moderate to severe hidradenitis suppurativa (HS) in people 12 years and older.
  • To treat moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older.
  • To treat moderate to severe ulcerative colitis (UC) in adults. It is not known if adalimumab products are effective in people who stopped responding to or could not tolerate TNF-blocker medicines.
  • To treat moderate to severe chronic (lasting a long time) plaque psoriasis (Ps) in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
  • To treat non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.
Important Safety Information for Adalimumab-adbm (adalimumab-adbm) injection, for subcutaneous use

This important information also applies to CYLTEZO® (adalimumab-adbm) injection for subcutaneous use. 

What is the most important information I should know about Adalimumab-adbm?

You should discuss the potential benefits and risks of Adalimumab-adbm with your doctor. Adalimumab-adbm is a TNF-blocker medicine that can lower the ability of your immune system to fight infections. You should not start taking Adalimumab-adbm if you have any kind of infection unless your doctor says it is okay.

  • Serious infections have happened in people taking adalimumab products. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. Your doctor should test you for TB before starting Adalimumab-adbm and check you closely for signs and symptoms of TB during treatment with Adalimumab-adbm, even if your TB test was negative. If your doctor feels you are at risk, you may be treated with medicine for TB.
  • Cancer. For children and adults taking TNF blockers, including Adalimumab-adbm, the chances of getting lymphoma or other cancers may increase. There have been cases of unusual cancers in children, teenagers, and young adults using TNF blockers. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including Adalimumab-adbm, your chances of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated; tell your doctor if you have a bump or open sore that doesn’t heal.

What should I tell my doctor BEFORE starting Adalimumab-adbm?

Tell your doctor about all of your health conditions, including if you:

  • Have an infection, are being treated for infection, or have symptoms of an infection.
  • Get a lot of infections or have infections that keep coming back.
  • Have diabetes.
  • Have TB or have been in close contact with someone with TB, or were born in, lived in, or traveled where there is more risk for getting TB.
  • Live or have lived in an area (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections, such as histoplasmosis, coccidioidomycosis, or blastomycosis. These infections may happen or become more severe if you use Adalimumab-adbm. Ask your doctor if you are unsure whether you have lived in an area where these infections are common.
  • Have or have had hepatitis B.
  • Are scheduled for major surgery.
  • Have or have had cancer.
  • Have numbness or tingling or a nervous system disease such as multiple sclerosis or Guillain-Barré syndrome.
  • Have or had heart failure.
  • Have recently received or are scheduled to receive a vaccine. Adalimumab-adbm patients may receive vaccines, except for live vaccines. Children should be brought up to date on all vaccines before starting Adalimumab-adbm.
  • Are allergic to rubber or latex.
  • Are allergic to any Adalimumab-adbm ingredients.
  • Are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed.
  • Have a baby and you were using Adalimumab-adbm during your pregnancy. Tell your baby’s doctor before your baby receives any vaccines.

Also tell your doctor about all the medicines you take. You should not take Adalimumab-adbm with ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab). Tell your doctor if you have ever used RITUXAN® (rituximab), IMURAN® 
(azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).

What should I watch for AFTER starting Adalimumab-adbm?

Adalimumab-adbm can cause serious side effects, including:

  • Serious infections. These include TB and infections caused by viruses, fungi, or bacteria. Symptoms related to TB include a cough, low-grade fever, weight loss, 
    or loss of body fat and muscle.
  • Hepatitis B infection in carriers of the virus. Symptoms include muscle aches, feeling very tired, dark urine, skin or eyes that look yellow, little or no appetite, 
    vomiting, clay-colored bowel movements, fever, chills, stomach discomfort, and skin rash.
  • Allergic reactions. Symptoms of a serious allergic reaction include hives; trouble breathing; and swelling of your face, eyes, lips, or mouth.
  • Nervous system problems. Signs and symptoms include numbness or tingling, problems with your vision, weakness in your arms or legs, and dizziness.
  • Blood problems (decreased blood cells that help fight infections or stop bleeding). Symptoms include a fever that does not go away, bruising or bleeding very 
    easily, or looking very pale.
  • Heart failure (new or worsening). Symptoms include shortness of breath, swelling of your ankles or feet, and sudden weight gain.
  • Immune reactions, including a lupus-like syndrome. Symptoms include chest discomfort or pain that does not go away, shortness of breath, joint pain, or rash on your cheeks or arms that gets worse in the sun.
  • Liver problems. Symptoms include feeling very tired, skin or eyes that look yellow, poor appetite or vomiting, and pain on the right side of your stomach 
    (abdomen). These problems can lead to liver failure and death.
  • Psoriasis (new or worsening). Symptoms include red scaly patches or raised bumps that are filled with pus.

Call your doctor or get medical care right away if you develop any of the above symptoms.

The most common side effects of Adalimumab-adbm include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all the possible side effects with Adalimumab-adbm. Tell your doctor if you have any side effect that bothers you or that does not go away.

Remember to tell your doctor right away if you have an infection or symptoms of an infection, including:

  • Fever, sweats, or chills
  • Muscle aches
  • Cough
  • Shortness of breath
  • Blood in phlegm
  • Weight loss
  • Warm, red, or painful skin or sores on your body
  • Diarrhea or stomach pain
  • Burning when you urinate
  • Urinating more often than normal
  • Feeling very tired

These are not all the possible side effects of Adalimumab-adbm. For more information, speak with your doctor or pharmacist.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CL-AA-100003 OCT 2025

Please see the Medication Guide and Instructions for Use for Adalimumab-adbm. Please see the Medication Guide and Instructions for Use for CYLTEZO.